Emblaveo is a fixed-dose IV treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
Metronidazole 500 mg orally twice a day for ... single daily dosing may be substituted Clotrimazole 100 mg vaginal tablet for 7 days OR Clotrimazole 100 mg vaginal tablet, two tablets for 3 ...
Oral metronidazole and vancomycin have been compared ... Comparisons have been made between vancomycin dosage strengths and relative efficacies. Forty-six hospitalized patients with underlying ...
ceftazidime and metronidazole; (2) loading doses for continuous infusion of vancomycin; and (3) dosing intervals for gentamicin and amikacin. Conclusions A considerable inter-centre variability of ...
The mice in the FMT groups were subjected to antibiotic interventions and depletion of the host gut microbiota by via oral gavage of a 3-day broad-spectrum antibiotic cocktail regimen (vancomycin, 100 ...
4d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
GlobalData on MSN2d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback